Neurotrophic Keratitis Epidemiology Summary
- In 2025, the total number of diagnosed prevalent cases of neurotrophic keratitis in the 7MM was approximately 60,000. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases approximately 40,000.
- Among EU4 and the UK, Germany accounted for the highest diagnosed prevalence of neurotrophic keratitis, with approximately 4,000 of the total cases. In contrast, with only approximately 2,000 cases, Spain reported the lowest diagnosed prevalence of neurotrophic keratitis in 2025.
- Female predominance is observed across the 7MM, particularly in the US and EU4 and the UK, likely reflecting differences in the prevalence of underlying ocular surface disorders, dry eye disease, and autoimmune conditions, along with biological susceptibility. Although the magnitude of female predominance varies across individual markets, females continue to account for a slightly higher proportion of diagnosed cases in several markets.
- Stage I remains the predominant neurotrophic keratitis stage across the 7MM, followed by Stage II and Stage III, suggesting improving recognition of earlier disease. However, the substantial proportion diagnosed in later stages indicates that delayed diagnosis and disease progression remain important challenges.
- The true epidemiological burden of neurotrophic keratitis remains underestimated due to under diagnosis, delayed diagnosis, and limited diagnosis-specific epidemiological data. Frequent under-recognition and misdiagnosis, particularly in early or mild disease, contribute to the relatively low diagnosis rate across the 7MM.
- Improving disease recognition and diagnostic practices is expected to expand the identifiable neurotrophic keratitis patient pool. Japan has the lowest diagnosed prevalence among the 7MM, likely reflecting differences in diagnostic practices, referral patterns, and disease recognition compared with the US and Europe. Increased awareness and wider adoption of standardized diagnostic assessments are expected to improve case identification.
DelveInsight’s “Neurotrophic Keratitis Epidemiology Forecast – 2036” report delivers an in depth understanding of neurotrophic keratitis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Neurotrophic Keratitis Understanding
Neurotrophic Keratitis Overview
Neurotrophic Keratitis, also known as Neurotrophic Keratopathy, is a rare, progressive degenerative corneal disease caused by impairment of trigeminal nerve innervation, resulting in reduced or absent corneal sensation. The main risk factors for neurotrophic keratitis include herpes simplex and herpes zoster infections, trigeminal neuralgia surgery, acoustic neuroma, ocular and orbital surgery, facial trauma, herpetic keratitis, chemical and thermal injuries, LASIK, keratoplasty, cataract surgery, contact lens wear, chronic use of topical ocular medications, and diabetes mellitus.
Neurotrophic Keratitis Diagnosis
Neurotrophic Keratitis is diagnosed based on identifying characteristic symptoms, a detailed patient and family history, a thorough clinical evaluation, and a variety of specialized tests. Individuals with unexplained signs of reduced corneal sensitivity and damage to the cornea are suspected for diagnosis. Neurotrophic keratitis is diagnosed based on assessment of corneal sensitivity together with evaluation of ocular surface abnormalities and associated clinical findings. Corneal sensitivity assessment is essential to confirm diagnosis and assess the severity of corneal nerve impairment. Fluorescein staining is used to identify epithelial abnormalities, while Schirmer testing evaluates tear production. Slit-lamp examination assesses corneal scarring, neovascularization, persistent epithelial defects, and stromal involvement. In vivo confocal microscopy can further support diagnosis by visualizing the sub-basal corneal nerve plexus.
Further details related to country-based variations are provided in the report...
Neurotrophic Keratitis Epidemiology
Key Findings from Neurotrophic Keratitis Epidemiological Analysis and Forecast
- According to DelveInsight’s analysis, approximately 20,000 males and 25,000 females were affected with neurotrophic keratitis in the US in 2025, depicting a clear gender disparity due to hormonal factors.
- Across EU4 and the UK, approximately 15,000 diagnosed prevalent cases were reported in 2025. Germany accounted for the largest share, contributing around 4,000 diagnosed prevalent cases, followed by the UK.
- According to DelveInsight’s estimates, Stage I neurotrophic keratitis accounted for the highest number of diagnosed prevalent cases across EU4 and the UK in 2025, with approximately 5,000 cases, followed by Stage II (~4,000 cases) and Stage III (~3,000 cases).
- Japan accounted for nearly 3,000 diagnosed prevalent cases of neurotrophic keratitis in 2025, representing only a small proportion of the total prevalent patient population.
Industry Experts and Physician Views for Neurotrophic Keratitis
To keep up with neurotrophic keratitis patient trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on neurotrophic keratitis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 20+ KOLs to gather insights at country level. Centers such as the National Jewish Health, Oregon Health & Science University, Hannover Medical School, University of Sassari, and Barcelona University etc. were contacted.
Scope of the Neurotrophic Keratitis Epidemiology Report
- The report covers a segment of an executive summary, a descriptive overview of neurotrophic keratitis, explaining its causes, signs, symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Neurotrophic Keratitis Epidemiology Report Insights
- Neurotrophic Keratitis Patient Population Forecast
Neurotrophic Keratitis Epidemiology Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
Explore the Neurotrophic Keratitis Market Insight, Epidemiology, and Market Forecast to 2036 for key trends, emerging therapies, and growth opportunities.
FAQs
- What are the disease risks, burdens, and unmet needs of neurotrophic keratitis?
- What will be the growth opportunities across the 7MM concerning the patient population with neurotrophic keratitis?
- What is the neurotrophic keratitis prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What is the historical and forecasted neurotrophic keratitis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy Neurotrophic Keratitis Epidemiology Insights Report
- Insights on neurotrophic keratitis burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- Clear methodology, validated assumptions, and data-driven rationale to assess the neurotrophic keratitis epidemiology analysis and patient population trends.



